|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
MX356947B
(es)
|
2011-08-23 |
2018-06-20 |
Roche Glycart Ag |
Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
US10087250B2
(en)
|
2012-10-08 |
2018-10-02 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
JP2016507523A
(ja)
|
2013-02-05 |
2016-03-10 |
エンクマフ アーゲー |
ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
|
|
AU2014222779B2
(en)
|
2013-02-26 |
2018-08-30 |
Roche Glycart Ag |
Bispecific T cell activating antigen binding molecules
|
|
TWI697334B
(zh)
|
2013-06-04 |
2020-07-01 |
美商再生元醫藥公司 |
藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
TWI634900B
(zh)
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
MX379210B
(es)
*
|
2014-02-07 |
2025-03-10 |
Univ Mcmaster |
Acoplador trifuncional de antígeno de células t y métodos y usos del mismo.
|
|
WO2015130975A1
(en)
|
2014-02-28 |
2015-09-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating skin infection by administering an il-4r antagonist
|
|
MA40510A
(fr)
|
2014-08-04 |
2017-06-14 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
|
|
AU2015329965A1
(en)
|
2014-10-09 |
2017-04-27 |
Engmab Sàrl |
Bispecific antibodies against CD3epsilon and ROR1
|
|
SG11201702976TA
(en)
|
2014-11-20 |
2017-05-30 |
Hoffmann La Roche |
T cell activating bispecific antigen binding molecules agiant folr1 and cd3
|
|
EP3023437A1
(en)
*
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
RS60615B1
(sr)
|
2014-11-20 |
2020-08-31 |
Hoffmann La Roche |
Zajednički laki lanci i postupci upotrebe
|
|
ES2926673T3
(es)
|
2014-11-20 |
2022-10-27 |
Hoffmann La Roche |
Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1
|
|
EP3029068A1
(en)
*
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
MX2017013297A
(es)
*
|
2015-04-13 |
2018-06-19 |
Pfizer |
Anticuerpos terapeuticos y sus usos.
|
|
RU2706582C2
(ru)
|
2015-04-13 |
2019-11-19 |
Пфайзер Инк. |
Химерные антигенные рецепторы, нацеленные на антиген созревания B-клеток
|
|
EP3466967A1
(en)
|
2015-05-18 |
2019-04-10 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
CN108350073B
(zh)
*
|
2015-08-03 |
2022-03-18 |
英格玛布有限责任公司 |
针对bcma的单克隆抗体
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
PT3337824T
(pt)
|
2015-08-17 |
2020-09-10 |
Janssen Pharmaceutica Nv |
Anticorpos anti-bcma, moléculas de ligação a antigénio biespecíficas que ligam bcma e cd3, e suas utilizações
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
KR20180073561A
(ko)
|
2015-10-02 |
2018-07-02 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
|
|
KR102850929B1
(ko)
|
2015-12-09 |
2025-08-27 |
에프. 호프만-라 로슈 아게 |
항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
IL313507A
(en)
|
2016-02-03 |
2024-08-01 |
Amgen Res Munich Gmbh |
Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
|
|
IL260920B
(en)
|
2016-02-03 |
2022-09-01 |
Amgen Res Munich Gmbh |
Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof
|
|
HK1259075A1
(zh)
|
2016-02-17 |
2019-11-22 |
Seattle Genetics, Inc. |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
LT3433280T
(lt)
|
2016-03-22 |
2023-07-10 |
F. Hoffmann-La Roche Ag |
Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
|
|
US10603380B2
(en)
|
2016-04-01 |
2020-03-31 |
Kite Pharma, Inc. |
Chimeric antigen and T cell receptors and methods of use
|
|
TWI761831B
(zh)
*
|
2016-04-01 |
2022-04-21 |
美商凱特製藥公司 |
嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途
|
|
DK3436030T3
(da)
|
2016-04-01 |
2022-11-21 |
Kite Pharma Inc |
Kimæriske receptorer og fremgangsmåder til anvendelse deraf
|
|
IL262321B2
(en)
|
2016-04-15 |
2024-09-01 |
Novartis Ag |
Preparations and methods for selective protein expression
|
|
KR20190053835A
(ko)
|
2016-06-21 |
2019-05-20 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
|
MX2019001469A
(es)
|
2016-08-01 |
2019-10-02 |
Novartis Ag |
Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
|
|
AU2017306432A1
(en)
|
2016-08-02 |
2019-03-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
EP4442323A3
(en)
|
2016-09-01 |
2025-01-01 |
Regeneron Pharmaceuticals, Inc. |
Methods for preventing or treating allergy by administering an il-4r antagonist
|
|
US20180064758A1
(en)
*
|
2016-09-05 |
2018-03-08 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CN114395048B
(zh)
*
|
2016-09-14 |
2025-01-28 |
特纳奥尼股份有限公司 |
Cd3结合抗体
|
|
ES2897217T3
(es)
|
2016-09-30 |
2022-02-28 |
Hoffmann La Roche |
Anticuerpos biespecíficos frente a p95HER2
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
EP4295918A3
(en)
*
|
2016-11-02 |
2024-03-20 |
Bristol-Myers Squibb Company |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CN116284402A
(zh)
|
2016-12-21 |
2023-06-23 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
FI3561057T3
(fi)
*
|
2016-12-22 |
2025-10-07 |
Daiichi Sankyo Co Ltd |
Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä
|
|
CN108341872B
(zh)
*
|
2017-01-23 |
2020-05-19 |
科济生物医药（上海）有限公司 |
靶向bcma的抗体及其应用
|
|
JP2020506700A
(ja)
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
|
|
CA3049689A1
(en)
*
|
2017-02-06 |
2018-08-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for augmenting antibody mediated receptor signaling
|
|
IL268554B2
(en)
|
2017-02-08 |
2025-03-01 |
Dragonfly Therapeutics Inc |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
SG11201907253VA
(en)
*
|
2017-02-10 |
2019-09-27 |
Dragonfly Therapeutics Inc |
Proteins binding bcma, nkg2d and cd16
|
|
WO2018151836A1
(en)
|
2017-02-17 |
2018-08-23 |
Fred Hutchinson Cancer Research Center |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
CN108456250B
(zh)
*
|
2017-02-17 |
2025-11-28 |
恺兴生命科技(上海)有限公司 |
靶向il-13ra2的抗体及其应用
|
|
CA3235295C
(en)
|
2017-02-20 |
2024-11-19 |
Dragonfly Therapeutics, Inc. |
Proteins binding her2, nkg2d and cd16
|
|
AU2018228719B2
(en)
|
2017-02-28 |
2023-03-30 |
Affimed Gmbh |
Tandem diabody for CD16A-directed NK-cell engagement
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
JP7356354B2
(ja)
|
2017-05-12 |
2023-10-04 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
|
|
WO2018213335A1
(en)
|
2017-05-16 |
2018-11-22 |
Scalmibio, Inc. |
Activatable antibodies and methods of use thereof
|
|
KR102742528B1
(ko)
|
2017-06-20 |
2024-12-16 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
CA3065951A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneoone, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
WO2019028367A1
(en)
|
2017-08-04 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
|
|
AU2018314236B2
(en)
|
2017-08-11 |
2025-02-06 |
Apterna Limited |
RNA aptamers against transferrin receptor (TfR)
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
CN118557697A
(zh)
|
2017-09-14 |
2024-08-30 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于癌症的组合治疗
|
|
WO2019053613A2
(en)
|
2017-09-14 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
POLY THERAPY FOR THE TREATMENT OF CANCER
|
|
EP3694878A1
(en)
|
2017-09-14 |
2020-08-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
TWI713843B
(zh)
*
|
2017-09-30 |
2020-12-21 |
大陸商科濟生物醫藥(上海)有限公司 |
標靶bcma的抗體及其應用
|
|
WO2019071358A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
|
|
CA3079407A1
(en)
|
2017-10-18 |
2019-04-25 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
AU2018369883A1
(en)
|
2017-11-15 |
2020-05-28 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
|
|
SG11202005005YA
(en)
|
2017-11-30 |
2020-06-29 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
UA128757C2
(uk)
|
2017-12-22 |
2024-10-16 |
Тенеобіо, Інк. |
Антитіла, які містять тільки важкі ланцюги, що зв'язуються з cd22
|
|
MX2020006715A
(es)
*
|
2017-12-27 |
2020-08-20 |
Teneobio Inc |
Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
|
|
EP3737408A1
(en)
|
2018-01-08 |
2020-11-18 |
Novartis AG |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
AU2019215031B2
(en)
|
2018-01-31 |
2025-10-09 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
US11884733B2
(en)
|
2018-02-08 |
2024-01-30 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the NKG2D receptor
|
|
CA3089287A1
(en)
|
2018-02-08 |
2019-08-15 |
Genentech, Inc. |
Bispecific antigen-binding molecules and methods of use
|
|
US12384847B2
(en)
|
2018-02-08 |
2025-08-12 |
Dragonfly Therapeutics, Inc. |
Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US12215157B2
(en)
|
2018-02-20 |
2025-02-04 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
|
|
CA3089230A1
(en)
|
2018-03-02 |
2019-09-06 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
SG11202009036YA
(en)
|
2018-03-30 |
2020-10-29 |
Merus Nv |
Multivalent antibody
|
|
KR20200143436A
(ko)
|
2018-04-13 |
2020-12-23 |
아피메트 게엠베하 |
Nk 세포 결합 항체 융합 구조체
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
EP3790629A1
(en)
|
2018-05-11 |
2021-03-17 |
CRISPR Therapeutics AG |
Methods and compositions for treating cancer
|
|
MA52624A
(fr)
|
2018-05-13 |
2021-03-24 |
Regeneron Pharma |
Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
|
|
JOP20200292A1
(ar)
|
2018-05-16 |
2020-11-15 |
Stichting Vumc |
Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
JP7398396B2
(ja)
|
2018-06-01 |
2023-12-14 |
ノバルティス アーゲー |
Ｂｃｍａに対する結合分子及びその使用
|
|
US20210123075A1
(en)
|
2018-06-08 |
2021-04-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
WO2020018825A1
(en)
|
2018-07-19 |
2020-01-23 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with bcma specificity and uses thereof
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
CN116769032A
(zh)
|
2018-07-20 |
2023-09-19 |
坦尼奥第二公司 |
与cd19结合的重链抗体
|
|
MA53284A
(fr)
|
2018-08-08 |
2022-01-26 |
Dragonfly Therapeutics Inc |
Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
WO2020047452A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
|
CN112125974B
(zh)
*
|
2018-09-25 |
2022-04-15 |
上海邦耀生物科技有限公司 |
靶向bcma蛋白的抗体、嵌合抗原受体和药物
|
|
JP2022509454A
(ja)
|
2018-10-31 |
2022-01-20 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
癌の処置法
|
|
WO2020132600A1
(en)
*
|
2018-12-20 |
2020-06-25 |
Cedars-Sinai Medical Center |
Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
|
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
|
CN109678961A
(zh)
*
|
2019-01-15 |
2019-04-26 |
深圳市南科生物工程有限公司 |
一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
EP3930763A1
(en)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Mesoporous silica particles compositions for viral delivery
|
|
PH12021552123A1
(en)
*
|
2019-03-21 |
2022-08-22 |
Regeneron Pharma |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
MX2021012205A
(es)
|
2019-04-05 |
2022-02-21 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma.
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
CN113939319A
(zh)
|
2019-04-30 |
2022-01-14 |
克里斯珀医疗股份公司 |
靶向cd19的基因工程化t细胞针对b细胞恶性肿瘤的同种异体细胞疗法
|
|
KR20220005058A
(ko)
*
|
2019-05-03 |
2022-01-12 |
셀진 코포레이션 |
항-bcma 항체 접합체, 그를 포함하는 조성물, 및 그의 제조 및 사용 방법
|
|
EP3972998A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
|
JP7665538B2
(ja)
|
2019-06-14 |
2025-04-21 |
テネオバイオ， インコーポレイテッド |
Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
|
|
US11504426B2
(en)
|
2019-08-05 |
2022-11-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
|
|
AU2020326713A1
(en)
|
2019-08-05 |
2022-02-17 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
CN120204384A
(zh)
|
2019-08-06 |
2025-06-27 |
葛兰素史密斯克莱知识产权发展有限公司 |
生物药物组合物和相关方法
|
|
EP4065164A4
(en)
*
|
2019-11-26 |
2024-03-27 |
Shanghai Epimab Biotherapeutics Co., Ltd. |
ANTIBODIES AGAINST CD3 AND BCMA AND BISPECIFIC BINDING PROTEINS PRODUCED THEREOF
|
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
US20230055143A1
(en)
*
|
2019-12-20 |
2023-02-23 |
Medimmune, Llc |
Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3
|
|
TW202135859A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
組合療法
|
|
JP2023509708A
(ja)
|
2020-01-03 |
2023-03-09 |
マレンゴ・セラピューティクス，インコーポレーテッド |
抗ｔｃｒ抗体分子およびその使用
|
|
CN111234020B
(zh)
*
|
2020-01-23 |
2020-10-23 |
和铂医药(苏州)有限公司 |
一种bcma结合蛋白及其制备方法和应用
|
|
WO2021168274A1
(en)
|
2020-02-21 |
2021-08-26 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
US20230078007A1
(en)
*
|
2020-02-24 |
2023-03-16 |
The Regents Of The University Of California |
In-series synthetic receptor and-gate circuits for expression of a therapeutic payload by engineered cells
|
|
CN115175695A
(zh)
|
2020-02-27 |
2022-10-11 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
WO2021173995A2
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
UY40003A
(es)
|
2020-04-29 |
2023-03-31 |
Teneobio Inc |
Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
|
|
EP4186564A1
(en)
|
2020-04-29 |
2023-05-31 |
Teneoone, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
TW202208428A
(zh)
|
2020-05-06 |
2022-03-01 |
美商蜻蜓醫療公司 |
結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
|
|
MX2022014166A
(es)
|
2020-05-11 |
2022-12-02 |
Janssen Biotech Inc |
Metodos para tratar el mieloma multiple.
|
|
WO2021234560A1
(en)
|
2020-05-19 |
2021-11-25 |
Janssen Biotech, Inc. |
Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
PE20231080A1
(es)
|
2020-06-19 |
2023-07-17 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y cd19
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
CA3189297A1
(en)
|
2020-06-30 |
2022-01-06 |
Nathan Trinklein |
Multi-specific antibodies binding to bcma
|
|
IL299508A
(en)
|
2020-07-01 |
2023-02-01 |
Ars Pharmaceuticals Inc |
Anti-asgr1 antibody conjugates and uses thereof
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
MX2023002107A
(es)
|
2020-08-21 |
2023-03-15 |
Novartis Ag |
Composiciones y metodos para la generacion in vivo de celulas que expresan car.
|
|
TW202233677A
(zh)
|
2020-11-02 |
2022-09-01 |
新加坡商蜂鳥生物科技私人有限公司 |
Bcma/taci抗原結合分子
|
|
WO2022135468A1
(zh)
*
|
2020-12-23 |
2022-06-30 |
信达生物制药(苏州)有限公司 |
抗bcma×cd3双特异性抗体及其用途
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
CA3210069A1
(en)
*
|
2021-03-03 |
2022-09-09 |
Tong Zhu |
Antibody-drug conjugates comprising an anti-bcma antibody
|
|
US20240158505A1
(en)
*
|
2021-03-26 |
2024-05-16 |
Theranotics Co., Ltd. |
B7-h3 antibody or antigen-binding fragment thereof, and use thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
|
EP4330381A1
(en)
|
2021-04-27 |
2024-03-06 |
Novartis AG |
Viral vector production system
|
|
TW202243689A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥
|
|
JP2024521187A
(ja)
|
2021-05-28 |
2024-05-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
ガンの治療のための組み合わせ療法
|
|
US12016923B2
(en)
|
2021-06-01 |
2024-06-25 |
Triumvira Immunologics Usa, Inc. |
Claudin 18.2 T cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
WO2023012669A2
(en)
|
2021-08-03 |
2023-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmaceutical compositions and stable isotope labeling peptide mapping method
|
|
TW202323521A
(zh)
|
2021-08-20 |
2023-06-16 |
瑞士商諾華公司 |
製備表現嵌合抗原受體的細胞之方法
|
|
EP4397685A4
(en)
*
|
2021-09-03 |
2025-10-22 |
Novoprotein Scient Inc |
HUMANIZED ANTI-CD3 ANTIBODY
|
|
EP4412713A1
(en)
|
2021-10-05 |
2024-08-14 |
GlaxoSmithKline Intellectual Property Development Ltd |
Combination therapies for treating cancer
|
|
IL312503A
(en)
|
2021-11-03 |
2024-07-01 |
Janssen Biotech Inc |
Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
|
|
CN118591560A
(zh)
|
2022-01-25 |
2024-09-03 |
葛兰素史密斯克莱知识产权发展有限公司 |
癌症的组合疗法
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
TW202409280A
(zh)
|
2022-07-08 |
2024-03-01 |
新加坡科技研究局 |
Cnx抗原結合分子
|
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024121711A1
(en)
|
2022-12-05 |
2024-06-13 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treatment using b-cell maturation antigen antagonists
|
|
US12173081B2
(en)
|
2023-03-21 |
2024-12-24 |
Biograph 55, Inc. |
CD19/CD38 multispecific antibodies
|
|
CN120981456A
(zh)
|
2023-05-24 |
2025-11-18 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
US20250242056A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
US20250262300A1
(en)
|
2024-02-16 |
2025-08-21 |
Kite Pharma, Inc. |
Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|